APO Research
Talk to an analyst

APO RESEARCH · REPORT

Cell Therapy CDMO

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Cell Therapy CDMO Market Analysis and Forecast 2026-2032

4 January 2026204 pages

Choose your research edition.

Industry ResearchCell Therapy CDMO Industry Research Report 2026133 pages · $2,950 USDIndustry Growth & TrendsGlobal Cell Therapy CDMO Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal Cell Therapy CDMO Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Cell Therapy CDMO Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal Cell Therapy CDMO Market Analysis and Forecast 2026-2032204 pages · $4,950 USD

Market perspective

The global Cell Therapy CDMO market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Cell Therapy CDMO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Cell Therapy CDMO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Cell Therapy CDMO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Cell Therapy CDMO is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Cell Therapy CDMO include Catalent, Lonza, Charles River, FUJIFILM Diosynth Biotechnologies, Exothera, Pharmaron, OBiO, AGC Biologics and Cytiva, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Cell Therapy CDMO, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Cell Therapy CDMO, also provides the revenue of main regions and countries. Of the upcoming market potential for Cell Therapy CDMO, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Cell Therapy CDMO revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Cell Therapy CDMO market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Cell Therapy CDMO revenue, projected growth trends, production technology, application and end-user industry.

Cell Therapy CDMO Segment by Company

Catalent

Lonza

Charles River

FUJIFILM Diosynth Biotechnologies

Exothera

Pharmaron

OBiO

AGC Biologics

Cytiva

ThermoGenesis

eXmoor Pharma

Advanced Therapies

Catalent Biologics

Patheon Pharma Services

Sartorius

Genezen

The Discovery Labs

Cell Therapy CDMO Segment by Type

Autologous Cell Therapy CDMO

Allogeneic Cell Therapy CDMO

Viral Vector and Gene Editing CDMO

Cell Therapy CDMO Segment by Application

Commercial

Academic Research

Others

Cell Therapy CDMO Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cell Therapy CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Cell Therapy CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cell Therapy CDMO.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Cell Therapy CDMO in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Cell Therapy CDMO company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Cell Therapy CDMO revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Cell Therapy CDMO Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Autologous Cell Therapy CDMO Major Player Table 3. Allogeneic Cell Therapy CDMO Major Player Table 4. Viral Vector and Gene Editing CDMO Major Player Table 5. Global Cell Therapy CDMO Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Commercial Major Player Table 7. Academic Research Major Player Table 8. Others Major Player Table 9. Cell Therapy CDMO Industry Trends Table 10. Cell Therapy CDMO Industry Drivers Table 11. Cell Therapy CDMO Industry Opportunities and Challenges Table 12. Cell Therapy CDMO Industry Restraints Table 13. Global Cell Therapy CDMO Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Cell Therapy CDMO Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Cell Therapy CDMO Market Share by Region (2021-2026) Table 16. Global Cell Therapy CDMO Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Cell Therapy CDMO Market Share by Region (2027-2032) Table 18. Global Cell Therapy CDMO Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Cell Therapy CDMO Revenue Market Share by Players (2021-2026) Table 20. Global Cell Therapy CDMO Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Cell Therapy CDMO Key Players Headquarters & Area Served Table 22. Global Cell Therapy CDMO Players, Product Type & Application Table 23. Global Cell Therapy CDMO Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Cell Therapy CDMO by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Cell Therapy CDMO Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Cell Therapy CDMO Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Cell Therapy CDMO Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Cell Therapy CDMO Revenue Market Share by Type (2021-2026) Table 30. Global Cell Therapy CDMO Revenue Market Share by Type (2027-2032) Table 31. Global Cell Therapy CDMO Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Cell Therapy CDMO Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Cell Therapy CDMO Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Cell Therapy CDMO Revenue Market Share by Application (2021-2026) Table 35. Global Cell Therapy CDMO Revenue Market Share by Application (2027-2032) Table 36. Catalent Company Information Table 37. Catalent Business Overview Table 38. Catalent Cell Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Catalent Cell Therapy CDMO Product Portfolio Table 40. Catalent Recent Development Table 41. Lonza Company Information Table 42. Lonza Business Overview Table 43. Lonza Cell Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Lonza Cell Therapy CDMO Product Portfolio Table 45. Lonza Recent Development Table 46. Charles River Company Information Table 47. Charles River Business Overview Table 48. Charles River Cell Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Charles River Cell Therapy CDMO Product Portfolio Table 50. Charles River Recent Development Table 51. FUJIFILM Diosynth Biotechnologies Company Information Table 52. FUJIFILM Diosynth Biotechnologies Business Overview Table 53. FUJIFILM Diosynth Biotechnologies Cell Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. FUJIFILM Diosynth Biotechnologies Cell Therapy CDMO Product Portfolio Table 55. FUJIFILM Diosynth Biotechnologies Recent Development Table 56. Exothera Company Information Table 57. Exothera Business Overview Table 58. Exothera Cell Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Exothera Cell Therapy CDMO Product Portfolio Table 60. Exothera Recent Development Table 61. Pharmaron Company Information Table 62. Pharmaron Business Overview Table 63. Pharmaron Cell Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Pharmaron Cell Therapy CDMO Product Portfolio Table 65. Pharmaron Recent Development Table 66. OBiO Company Information Table 67. OBiO Business Overview Table 68. OBiO Cell Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. OBiO Cell Therapy CDMO Product Portfolio Table 70. OBiO Recent Development Table 71. AGC Biologics Company Information Table 72. AGC Biologics Business Overview Table 73. AGC Biologics Cell Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. AGC Biologics Cell Therapy CDMO Product Portfolio Table 75. AGC Biologics Recent Development Table 76. Cytiva Company Information Table 77. Cytiva Business Overview Table 78. Cytiva Cell Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Cytiva Cell Therapy CDMO Product Portfolio Table 80. Cytiva Recent Development Table 81. ThermoGenesis Company Information Table 82. ThermoGenesis Business Overview Table 83. ThermoGenesis Cell Therapy CDMO Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. ThermoGenesis Cell Therapy CDMO Product Portfolio Table 85. ThermoGenesis Recent Development Table 86. eXmoor Pharma Company Information Table 87. eXmoor Pharma Business Overview Table 88. eXmoor Pharma Cell Therapy CDMO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 89. eXmoor Pharma Cell Therapy CDMO Product Portfolio Table 90. eXmoor Pharma Recent Development Table 91. Advanced Therapies Company Information Table 92. Advanced Therapies Business Overview Table 93. Advanced Therapies Cell Therapy CDMO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 94. Advanced Therapies Cell Therapy CDMO Product Portfolio Table 95. Advanced Therapies Recent Development Table 96. Catalent Biologics Company Information Table 97. Catalent Biologics Business Overview Table 98. Catalent Biologics Cell Therapy CDMO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 99. Catalent Biologics Cell Therapy CDMO Product Portfolio Table 100. Catalent Biologics Recent Development Table 101. Patheon Pharma Services Company Information Table 102. Patheon Pharma Services Business Overview Table 103. Patheon Pharma Services Cell Therapy CDMO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 104. Patheon Pharma Services Cell Therapy CDMO Product Portfolio Table 105. Patheon Pharma Services Recent Development Table 106. Sartorius Company Information Table 107. Sartorius Business Overview Table 108. Sartorius Cell Therapy CDMO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 109. Sartorius Cell Therapy CDMO Product Portfolio Table 110. Sartorius Recent Development Table 111. Genezen Company Information Table 112. Genezen Business Overview Table 113. Genezen Cell Therapy CDMO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 114. Genezen Cell Therapy CDMO Product Portfolio Table 115. Genezen Recent Development Table 116. The Discovery Labs Company Information Table 117. The Discovery Labs Business Overview Table 118. The Discovery Labs Cell Therapy CDMO Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 119. The Discovery Labs Cell Therapy CDMO Product Portfolio Table 120. The Discovery Labs Recent Development Table 121. North America Cell Therapy CDMO Revenue by Type (2021-2026) & (US$ Million) Table 122. North America Cell Therapy CDMO Revenue by Type (2027-2032) & (US$ Million) Table 123. North America Cell Therapy CDMO Revenue by Application (2021-2026) & (US$ Million) Table 124. North America Cell Therapy CDMO Revenue by Application (2027-2032) & (US$ Million) Table 125. North America Cell Therapy CDMO Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 126. North America Cell Therapy CDMO Revenue by Country (2021-2026) & (US$ Million) Table 127. North America Cell Therapy CDMO Revenue by Country (US$ Million) & (2027-2032) Table 128. Europe Cell Therapy CDMO Revenue by Type (2021-2026) & (US$ Million) Table 129. Europe Cell Therapy CDMO Revenue by Type (2027-2032) & (US$ Million) Table 130. Europe Cell Therapy CDMO Revenue by Application (2021-2026) & (US$ Million) Table 131. Europe Cell Therapy CDMO Revenue by Application (2027-2032) & (US$ Million) Table 132. Europe Cell Therapy CDMO Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 133. Europe Cell Therapy CDMO Revenue by Country (2021-2026) & (US$ Million) Table 134. Europe Cell Therapy CDMO Revenue by Country (US$ Million) & (2027-2032) Table 135. China Cell Therapy CDMO Revenue by Type (2021-2026) & (US$ Million) Table 136. China Cell Therapy CDMO Revenue by Type (2027-2032) & (US$ Million) Table 137. China Cell Therapy CDMO Revenue by Application (2021-2026) & (US$ Million) Table 138. China Cell Therapy CDMO Revenue by Application (2027-2032) & (US$ Million) Table 139. Asia Cell Therapy CDMO Revenue by Type (2021-2026) & (US$ Million) Table 140. Asia Cell Therapy CDMO Revenue by Type (2027-2032) & (US$ Million) Table 141. Asia Cell Therapy CDMO Revenue by Application (2021-2026) & (US$ Million) Table 142. Asia Cell Therapy CDMO Revenue by Application (2027-2032) & (US$ Million) Table 143. Asia Cell Therapy CDMO Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 144. Asia Cell Therapy CDMO Revenue by Region (US$ Million) & (2021-2026) Table 145. Asia Cell Therapy CDMO Revenue by Region (US$ Million) & (2027-2032) Table 146. SAMEA Cell Therapy CDMO Revenue by Type (2021-2026) & (US$ Million) Table 147. SAMEA Cell Therapy CDMO Revenue by Type (2027-2032) & (US$ Million) Table 148. SAMEA Cell Therapy CDMO Revenue by Application (2021-2026) & (US$ Million) Table 149. SAMEA Cell Therapy CDMO Revenue by Application (2027-2032) & (US$ Million) Table 150. SAMEA Cell Therapy CDMO Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 151. SAMEA Cell Therapy CDMO Revenue by Country (2021-2026) & (US$ Million) Table 152. SAMEA Cell Therapy CDMO Revenue by Country (US$ Million) & (2027-2032) Table 153. Research Programs/Design for This Report Table 154. Authors List of This Report Table 155. Secondary Sources Table 156. Primary Sources List of Figures Figure 1. Cell Therapy CDMO Image Figure 2. Global Cell Therapy CDMO Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Cell Therapy CDMO Market Size Share 2021 VS 2025 VS 2032 Figure 4. Autologous Cell Therapy CDMO Image Figure 5. Allogeneic Cell Therapy CDMO Image Figure 6. Viral Vector and Gene Editing CDMO Image Figure 7. Global Cell Therapy CDMO Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Cell Therapy CDMO Market Size Share 2021 VS 2025 VS 2032 Figure 9. Commercial Image Figure 10. Academic Research Image Figure 11. Others Image Figure 12. Global Cell Therapy CDMO Market Size (US$ Million) & (2021-2032) Figure 13. Global Cell Therapy CDMO Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Cell Therapy CDMO Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Cell Therapy CDMO Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Cell Therapy CDMO Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Cell Therapy CDMO Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Cell Therapy CDMO Revenue Market Share by Type (2021-2032) Figure 20. Global Cell Therapy CDMO Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Cell Therapy CDMO Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Cell Therapy CDMO Revenue Market Share by Application (2021-2032) Figure 23. North America Cell Therapy CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Cell Therapy CDMO Revenue Share by Type (2021-2032) Figure 25. North America Cell Therapy CDMO Revenue Share by Application (2021-2032) Figure 26. North America Cell Therapy CDMO Revenue Share by Country (2021-2032) Figure 27. United States Cell Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Cell Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Cell Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Cell Therapy CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Cell Therapy CDMO Revenue Share by Type (2021-2032) Figure 32. Europe Cell Therapy CDMO Revenue Share by Application (2021-2032) Figure 33. Europe Cell Therapy CDMO Revenue Share by Country (2021-2032) Figure 34. Germany Cell Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Cell Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Cell Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Cell Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Cell Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Cell Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Cell Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Cell Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Cell Therapy CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Cell Therapy CDMO Revenue Share by Type (2021-2032) Figure 44. China Cell Therapy CDMO Revenue Share by Application (2021-2032) Figure 45. Asia Cell Therapy CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Cell Therapy CDMO Revenue Share by Type (2021-2032) Figure 47. Asia Cell Therapy CDMO Revenue Share by Application (2021-2032) Figure 48. Asia Cell Therapy CDMO Revenue Share by Region (2021-2032) Figure 49. Japan Cell Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Cell Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Cell Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Cell Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Cell Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Cell Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Cell Therapy CDMO Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Cell Therapy CDMO Revenue Share by Type (2021-2032) Figure 57. SAMEA Cell Therapy CDMO Revenue Share by Application (2021-2032) Figure 58. SAMEA Cell Therapy CDMO Revenue Share by Country (2021-2032) Figure 59. Brazil Cell Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Cell Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Cell Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Cell Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Cell Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Cell Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Cell Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Cell Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Cell Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Cell Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Cell Therapy CDMO Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Autologous Cell Therapy CDMO
  • Allogeneic Cell Therapy CDMO
  • Viral Vector and Gene Editing CDMO
Applications
  • Commercial
  • Academic Research
  • Others
Companies covered
  • Catalent
  • Lonza
  • Charles River
  • FUJIFILM Diosynth Biotechnologies
  • Exothera
  • Pharmaron
  • OBiO
  • AGC Biologics
  • Cytiva
  • ThermoGenesis
  • eXmoor Pharma
  • Advanced Therapies
  • Catalent Biologics
  • Patheon Pharma Services
  • Sartorius
  • Genezen
  • The Discovery Labs

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Cell Therapy CDMO Market by Type
  3. 1.2.1 Global Cell Therapy CDMO Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Autologous Cell Therapy CDMO
  5. 1.2.3 Allogeneic Cell Therapy CDMO
  6. 1.2.4 Viral Vector and Gene Editing CDMO
  7. 1.3 Cell Therapy CDMO Market by Application
  8. 1.3.1 Global Cell Therapy CDMO Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Commercial
  10. 1.3.3 Academic Research
  11. 1.3.4 Others
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Cell Therapy CDMO Market Dynamics
  1. 2.1 Cell Therapy CDMO Industry Trends
  2. 2.2 Cell Therapy CDMO Industry Drivers
  3. 2.3 Cell Therapy CDMO Industry Opportunities and Challenges
  4. 2.4 Cell Therapy CDMO Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Cell Therapy CDMO Market Perspective (2021-2032)
  2. 3.2 Global Cell Therapy CDMO Growth Trends by Region
  3. 3.2.1 Global Cell Therapy CDMO Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Cell Therapy CDMO Market Size by Region (2021-2026)
  5. 3.2.3 Global Cell Therapy CDMO Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Cell Therapy CDMO Revenue by Players
  2. 4.1.1 Global Cell Therapy CDMO Revenue by Players (2021-2026)
  3. 4.1.2 Global Cell Therapy CDMO Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Cell Therapy CDMO Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Cell Therapy CDMO Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Cell Therapy CDMO Key Players Headquarters & Area Served
  7. 4.4 Global Cell Therapy CDMO Players, Product Type & Application
  8. 4.5 Global Cell Therapy CDMO Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Cell Therapy CDMO Market CR5 and HHI
  11. 4.6.3 2025 Cell Therapy CDMO Tier 1, Tier 2, and Tier 3
5 Cell Therapy CDMO Market Size by Type
  1. 5.1 Global Cell Therapy CDMO Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Cell Therapy CDMO Revenue by Type (2021-2032)
  3. 5.3 Global Cell Therapy CDMO Revenue Market Share by Type (2021-2032)
6 Cell Therapy CDMO Market Size by Application
  1. 6.1 Global Cell Therapy CDMO Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Cell Therapy CDMO Revenue by Application (2021-2032)
  3. 6.3 Global Cell Therapy CDMO Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Catalent
  2. 7.1.1 Catalent Company Information
  3. 7.1.2 Catalent Business Overview
  4. 7.1.3 Catalent Cell Therapy CDMO Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Catalent Cell Therapy CDMO Product Portfolio
  6. 7.1.5 Catalent Recent Developments
  7. 7.2 Lonza
  8. 7.2.1 Lonza Company Information
  9. 7.2.2 Lonza Business Overview
  10. 7.2.3 Lonza Cell Therapy CDMO Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Lonza Cell Therapy CDMO Product Portfolio
  12. 7.2.5 Lonza Recent Developments
  13. 7.3 Charles River
  14. 7.3.1 Charles River Company Information
  15. 7.3.2 Charles River Business Overview
  16. 7.3.3 Charles River Cell Therapy CDMO Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Charles River Cell Therapy CDMO Product Portfolio
  18. 7.3.5 Charles River Recent Developments
  19. 7.4 FUJIFILM Diosynth Biotechnologies
  20. 7.4.1 FUJIFILM Diosynth Biotechnologies Company Information
  21. 7.4.2 FUJIFILM Diosynth Biotechnologies Business Overview
  22. 7.4.3 FUJIFILM Diosynth Biotechnologies Cell Therapy CDMO Revenue and Gross Margin (2021-2026)
  23. 7.4.4 FUJIFILM Diosynth Biotechnologies Cell Therapy CDMO Product Portfolio
  24. 7.4.5 FUJIFILM Diosynth Biotechnologies Recent Developments
  25. 7.5 Exothera
  26. 7.5.1 Exothera Company Information
  27. 7.5.2 Exothera Business Overview
  28. 7.5.3 Exothera Cell Therapy CDMO Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Exothera Cell Therapy CDMO Product Portfolio
  30. 7.5.5 Exothera Recent Developments
  31. 7.6 Pharmaron
  32. 7.6.1 Pharmaron Company Information
  33. 7.6.2 Pharmaron Business Overview
  34. 7.6.3 Pharmaron Cell Therapy CDMO Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Pharmaron Cell Therapy CDMO Product Portfolio
  36. 7.6.5 Pharmaron Recent Developments
  37. 7.7 OBiO
  38. 7.7.1 OBiO Company Information
  39. 7.7.2 OBiO Business Overview
  40. 7.7.3 OBiO Cell Therapy CDMO Revenue and Gross Margin (2021-2026)
  41. 7.7.4 OBiO Cell Therapy CDMO Product Portfolio
  42. 7.7.5 OBiO Recent Developments
  43. 7.8 AGC Biologics
  44. 7.8.1 AGC Biologics Company Information
  45. 7.8.2 AGC Biologics Business Overview
  46. 7.8.3 AGC Biologics Cell Therapy CDMO Revenue and Gross Margin (2021-2026)
  47. 7.8.4 AGC Biologics Cell Therapy CDMO Product Portfolio
  48. 7.8.5 AGC Biologics Recent Developments
  49. 7.9 Cytiva
  50. 7.9.1 Cytiva Company Information
  51. 7.9.2 Cytiva Business Overview
  52. 7.9.3 Cytiva Cell Therapy CDMO Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Cytiva Cell Therapy CDMO Product Portfolio
  54. 7.9.5 Cytiva Recent Developments
  55. 7.10 ThermoGenesis
  56. 7.10.1 ThermoGenesis Company Information
  57. 7.10.2 ThermoGenesis Business Overview
  58. 7.10.3 ThermoGenesis Cell Therapy CDMO Revenue and Gross Margin (2021-2026)
  59. 7.10.4 ThermoGenesis Cell Therapy CDMO Product Portfolio
  60. 7.10.5 ThermoGenesis Recent Developments
  61. 7.11 eXmoor Pharma
  62. 7.11.1 eXmoor Pharma Company Information
  63. 7.11.2 eXmoor Pharma Business Overview
  64. 7.11.3 eXmoor Pharma Cell Therapy CDMO Revenue and Gross Margin (2021-2026)
  65. 7.11.4 eXmoor Pharma Cell Therapy CDMO Product Portfolio
  66. 7.11.5 eXmoor Pharma Recent Developments
  67. 7.12 Advanced Therapies
  68. 7.12.1 Advanced Therapies Company Information
  69. 7.12.2 Advanced Therapies Business Overview
  70. 7.12.3 Advanced Therapies Cell Therapy CDMO Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Advanced Therapies Cell Therapy CDMO Product Portfolio
  72. 7.12.5 Advanced Therapies Recent Developments
  73. 7.13 Catalent Biologics
  74. 7.13.1 Catalent Biologics Company Information
  75. 7.13.2 Catalent Biologics Business Overview
  76. 7.13.3 Catalent Biologics Cell Therapy CDMO Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Catalent Biologics Cell Therapy CDMO Product Portfolio
  78. 7.13.5 Catalent Biologics Recent Developments
  79. 7.14 Patheon Pharma Services
  80. 7.14.1 Patheon Pharma Services Company Information
  81. 7.14.2 Patheon Pharma Services Business Overview
  82. 7.14.3 Patheon Pharma Services Cell Therapy CDMO Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Patheon Pharma Services Cell Therapy CDMO Product Portfolio
  84. 7.14.5 Patheon Pharma Services Recent Developments
  85. 7.15 Sartorius
  86. 7.15.1 Sartorius Company Information
  87. 7.15.2 Sartorius Business Overview
  88. 7.15.3 Sartorius Cell Therapy CDMO Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Sartorius Cell Therapy CDMO Product Portfolio
  90. 7.15.5 Sartorius Recent Developments
  91. 7.16 Genezen
  92. 7.16.1 Genezen Company Information
  93. 7.16.2 Genezen Business Overview
  94. 7.16.3 Genezen Cell Therapy CDMO Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Genezen Cell Therapy CDMO Product Portfolio
  96. 7.16.5 Genezen Recent Developments
  97. 7.17 The Discovery Labs
  98. 7.17.1 The Discovery Labs Company Information
  99. 7.17.2 The Discovery Labs Business Overview
  100. 7.17.3 The Discovery Labs Cell Therapy CDMO Revenue and Gross Margin (2021-2026)
  101. 7.17.4 The Discovery Labs Cell Therapy CDMO Product Portfolio
  102. 7.17.5 The Discovery Labs Recent Developments
8 North America
  1. 8.1 North America Cell Therapy CDMO Revenue (2021-2032)
  2. 8.2 North America Cell Therapy CDMO Revenue by Type (2021-2032)
  3. 8.2.1 North America Cell Therapy CDMO Revenue by Type (2021-2026)
  4. 8.2.2 North America Cell Therapy CDMO Revenue by Type (2027-2032)
  5. 8.3 North America Cell Therapy CDMO Revenue Share by Type (2021-2032)
  6. 8.4 North America Cell Therapy CDMO Revenue by Application (2021-2032)
  7. 8.4.1 North America Cell Therapy CDMO Revenue by Application (2021-2026)
  8. 8.4.2 North America Cell Therapy CDMO Revenue by Application (2027-2032)
  9. 8.5 North America Cell Therapy CDMO Revenue Share by Application (2021-2032)
  10. 8.6 North America Cell Therapy CDMO Revenue by Country
  11. 8.6.1 North America Cell Therapy CDMO Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Cell Therapy CDMO Revenue by Country (2021-2026)
  13. 8.6.3 North America Cell Therapy CDMO Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Cell Therapy CDMO Revenue (2021-2032)
  2. 9.2 Europe Cell Therapy CDMO Revenue by Type (2021-2032)
  3. 9.2.1 Europe Cell Therapy CDMO Revenue by Type (2021-2026)
  4. 9.2.2 Europe Cell Therapy CDMO Revenue by Type (2027-2032)
  5. 9.3 Europe Cell Therapy CDMO Revenue Share by Type (2021-2032)
  6. 9.4 Europe Cell Therapy CDMO Revenue by Application (2021-2032)
  7. 9.4.1 Europe Cell Therapy CDMO Revenue by Application (2021-2026)
  8. 9.4.2 Europe Cell Therapy CDMO Revenue by Application (2027-2032)
  9. 9.5 Europe Cell Therapy CDMO Revenue Share by Application (2021-2032)
  10. 9.6 Europe Cell Therapy CDMO Revenue by Country
  11. 9.6.1 Europe Cell Therapy CDMO Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Cell Therapy CDMO Revenue by Country (2021-2026)
  13. 9.6.3 Europe Cell Therapy CDMO Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Cell Therapy CDMO Revenue (2021-2032)
  2. 10.2 China Cell Therapy CDMO Revenue by Type (2021-2032)
  3. 10.2.1 China Cell Therapy CDMO Revenue by Type (2021-2026)
  4. 10.2.2 China Cell Therapy CDMO Revenue by Type (2027-2032)
  5. 10.3 China Cell Therapy CDMO Revenue Share by Type (2021-2032)
  6. 10.4 China Cell Therapy CDMO Revenue by Application (2021-2032)
  7. 10.4.1 China Cell Therapy CDMO Revenue by Application (2021-2026)
  8. 10.4.2 China Cell Therapy CDMO Revenue by Application (2027-2032)
  9. 10.5 China Cell Therapy CDMO Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Cell Therapy CDMO Revenue (2021-2032)
  2. 11.2 Asia Cell Therapy CDMO Revenue by Type (2021-2032)
  3. 11.2.1 Asia Cell Therapy CDMO Revenue by Type (2021-2026)
  4. 11.2.2 Asia Cell Therapy CDMO Revenue by Type (2027-2032)
  5. 11.3 Asia Cell Therapy CDMO Revenue Share by Type (2021-2032)
  6. 11.4 Asia Cell Therapy CDMO Revenue by Application (2021-2032)
  7. 11.4.1 Asia Cell Therapy CDMO Revenue by Application (2021-2026)
  8. 11.4.2 Asia Cell Therapy CDMO Revenue by Application (2027-2032)
  9. 11.5 Asia Cell Therapy CDMO Revenue Share by Application (2021-2032)
  10. 11.6 Asia Cell Therapy CDMO Revenue by Country
  11. 11.6.1 Asia Cell Therapy CDMO Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Cell Therapy CDMO Revenue by Country (2021-2026)
  13. 11.6.3 Asia Cell Therapy CDMO Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Cell Therapy CDMO Revenue (2021-2032)
  2. 12.2 SAMEA Cell Therapy CDMO Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Cell Therapy CDMO Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Cell Therapy CDMO Revenue by Type (2027-2032)
  5. 12.3 SAMEA Cell Therapy CDMO Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Cell Therapy CDMO Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Cell Therapy CDMO Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Cell Therapy CDMO Revenue by Application (2027-2032)
  9. 12.5 SAMEA Cell Therapy CDMO Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Cell Therapy CDMO Revenue by Country
  11. 12.6.1 SAMEA Cell Therapy CDMO Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Cell Therapy CDMO Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Cell Therapy CDMO Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst